# Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema

> **NCT04018833** · — · COMPLETED · sponsor: **Bernardete Pessoa MD** · enrollment: 40 (actual)

## Conditions studied

- Diabetic Macular Edema
- Diabetic Retinopathy

## Interventions

- **DRUG:** Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
- **DRUG:** Aflibercept 40 MG/ML Intraocular Solution [EYLEA]

## Key facts

- **NCT ID:** NCT04018833
- **Lead sponsor:** Bernardete Pessoa MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-01
- **Primary completion:** 2016-06-01
- **Final completion:** 2016-06-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04018833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04018833, "Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04018833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*